Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH2 | Q8IWU9 | 17/20 | 0.87 |
| ▸ | TPH1 | P17752 | 14/20 | 0.87 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | BRAF | P15056 | 1/20 | 0.62 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.60 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.60 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18036526 | 0.90 | TPH2 (0.86) | TPH2TPH1USP2ALDH1A1MAPK1 | |
| SCHEMBL18036499 | 0.89 | TPH2 (1.00) | TPH2TPH1USP2ALDH1A1MAPK1 | |
| SCHEMBL18036502 | 0.89 | TPH2 (1.00) | TPH2TPH1USP2ALDH1A1MAPK1 | |
| SCHEMBL18036514 | 0.88 | TPH2 (0.87) | TPH2TPH1USP2ALDH1A1MAPK1 | |
| SCHEMBL18036517 | 0.87 | TPH2 (1.00) | TPH2TPH1USP2ALDH1A1MAPK1 | |
| SCHEMBL18036530 | 0.86 | TPH2 (0.75) | TPH2TPH1USP2ALDH1A1MAPK1 | |
| SCHEMBL18036516 | 0.85 | TPH2 (0.88) | TPH2TPH1USP2ALDH1A1MAPK1 | |
| SCHEMBL18036512 | 0.82 | TPH2 (0.79) | TPH2TPH1USP2ALDH1A1MAPK1 | |
| SCHEMBL18053143 | 0.81 | TPH2 (0.89) | TPH2TPH1USP2ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL18036508 | 0.81 | TPH2 (0.88) | TPH2TPH1USP2ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262044-B1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-02-06 | — | — | EP | disclosed |
| EP-3262044-B1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-02-06 | — | — | EP | disclosed |
| US-20180051025-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-02-22 | — | — | US | disclosed |
| US-20180051025-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-02-22 | — | — | US | disclosed |
| US-20180051025-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-02-22 | — | — | US | disclosed |
| EP-3262044-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135199-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2016-09-01 | — | — | WO | disclosed |
| EP-3061761-A1 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2016-08-31 | — | — | EP | disclosed |
| EP-3061761-A1 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2016-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051025-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | TPH1, XDH, TPH2 | TPH2 3/4885TPH1 1/4885USP2 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.